Palliative parenteral nutrition use in patients with intestinal failure as a consequence of advanced pseudomyxoma peritonei: a case series

Article metrics



Pseudomyxoma peritonei (PMP) is a rare condition complicated by intra-abdominal spread that can cause multilevel gastrointestinal (GI) obstruction. Parenteral nutrition (PN) use in the context of palliative care and malignancy remains controversial. We describe the use of palliative PN in three patients with progressive PMP causing multilevel GI obstruction and intestinal failure. All patients received >90 days of PN. PN was safe in this cohort of patients. However, patient selection and the timing of intervention are important factors when considering the initiation of PN.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. 1

    Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA . Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 2008; 34: 196–201.

  2. 2

    Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M ESPEN. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr 2009; 28: 445–454.

  3. 3

    Hoda D, Jatoi A, Burnes J, Loprinzi C, Kelly D . Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution’s 20-year experience. Cancer 2005; 103: 863–868.

  4. 4

    Bozzetti F, Santarpia L, Pironi L, Thul P, Klek S, Gavazzi C et al. The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients. Ann Oncol 2014; 25: 487–493.

  5. 5

    Duerksen DR, Ting E, Thomson P, McCurdy K, Linscer J, Larsen-Celhar S et al. Is there a role for TPN in terminally ill patients with bowel obstruction? Nutrition 2004; 20: 760–763.

  6. 6

    Chermesh I, Mashiach T, Amit A, Haim N, Papier I, Efergan R et al. Home parenteral nutrition (HTPN) for incurable patients with cancer with gastrointestinal obstruction: do the benefits outweigh the risks? Med Oncol 2011; 28: 83–88.

Download references

Author information

Correspondence to B R Disney.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading